A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria

Parasite Immunology
Q De MastA J M van der Ven

Abstract

Macrophage migration inhibitory factor (MIF) has recently been implicated in the pathogenesis of malarial anaemia. However, field studies have reported contradictory results on circulating MIF concentrations in patients with clinically overt Plasmodium falciparum malaria. We determined plasma MIF levels over time in 10 healthy volunteers during experimental P. falciparum infection. Under fully controlled conditions, MIF levels decreased significantly during early blood-stage infection and reached a nadir at day 8 post-infection. A decrease in the number of circulating lymphocytes, which are an important source of MIF production, paralleled the decrease in MIF levels. Monocyte/macrophage counts remained unchanged. At MIF nadir, the anti-inflammatory cytokine interleukin (IL)-10, which is an inhibitor of T-cell MIF production, was detectable in only 2 of 10 volunteers. Plasma concentrations of the pro-inflammatory cytokines IL-8 and IL-1beta were only marginally elevated. We conclude that circulating MIF levels decrease early in blood-stage malaria as a result of the decline in circulating lymphocytes.

References

Sep 1, 1994·The American Journal of Tropical Medicine and Hygiene·I M ElhassanT G Theander
Nov 1, 1994·Transactions of the Royal Society of Tropical Medicine and Hygiene·I M LisseK Knudsen
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·M BacherR Bucala
Apr 18, 2000·Infection and Immunity·P KernN Wellinghausen
Feb 24, 2001·Infection and Immunity·L Hviid, K Kemp
Oct 29, 2002·The Journal of Infectious Diseases·Sujittra ChaisavaneeyakornVenkatachalam Udhayakumar
Sep 23, 2003·Nature Reviews. Immunology·Thierry Calandra, Thierry Roger
Feb 8, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Gordon A AwandareDouglas J Perkins
Apr 26, 2006·The Journal of Experimental Medicine·Michael A McDevittRichard Bucala
Oct 13, 2006·Malaria Journal·Ian A ClarkWilliam B Cowden

❮ Previous
Next ❯

Citations

Jul 14, 2009·The Journal of Infectious Diseases·Gordon A AwandareDouglas J Perkins
Apr 13, 2012·Journal of Parasitology Research·Marcelo T BozzaClaudia N Paiva
Sep 21, 2011·Malaria Journal·Adel DrissJonathan K Stiles
Mar 20, 2013·Malaria Journal·Marlies E van WolfswinkelPerry J van Genderen
Nov 24, 2011·International Journal of Biological Sciences·Juan de Dios Rosado, Miriam Rodriguez-Sosa
Nov 24, 2011·International Journal of Biological Sciences·Douglas J PerkinsJohn Michael Ong'echa
Dec 15, 2015·Journal of Tropical Medicine·Alberto Tobón-CastañoAndrés Felipe Miranda-Arboleda
Apr 5, 2011·Malaria Journal·Sedigheh ZakeriNavid D Djadid
Oct 13, 2012·Current Problems in Surgery·Merril T DaytonAlan R Posner
Sep 20, 2017·Infection and Immunity·Danielle I StanisicMichael F Good
Sep 23, 2021·Scientific Reports·Aurelie MiglarMuhammad Asghar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.